Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy - PubMed (original) (raw)

. 2021 Oct 14;7(1):36-45.

doi: 10.1016/j.ekir.2021.10.008. eCollection 2022 Jan.

Gerasimos Filippatos 3, Rajiv Agarwal 4, Stefan D Anker 5, Bertram Pitt 6, Luis M Ruilope 7 8 9, Juliana C N Chan 10 11 12, Adriaan Kooy 13 14 15, Kieran McCafferty 16, Guntram Schernthaner 17 18, Christoph Wanner 19, Amer Joseph 20, Markus F Scheerer 21, Charlie Scott 22, George L Bakris 23; FIDELIO-DKD Investigators

Affiliations

Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy

Peter Rossing et al. Kidney Int Rep. 2021.

Abstract

Introduction: FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease prOgression in Diabetic Kidney Disease) investigated the nonsteroidal, selective mineralocorticoid receptor (MR) antagonist finerenone in patients with CKD and type 2 diabetes (T2D). This analysis explores the impact of use of sodium-glucose cotransporter-2 inhibitor (SGLT-2i) on the treatment effect of finerenone.

Methods: Patients (N = 5674) with T2D, urine albumin-to-creatinine ratio (UACR) of 30 to 5000 mg/g and estimated glomerular filtration rate (eGFR) of 25 to <75 ml/min per 1.73 m2 receiving optimized renin-angiotensin system (RAS) blockade were randomized to finerenone or placebo. Endpoints were change in UACR and a composite kidney outcome (time to kidney failure, sustained decrease in eGFR ≥40% from baseline, or renal death) and key secondary cardiovascular outcomes (time to cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure) (ClinicalTrials.gov, NCT02540993).

Results: Of 5674 patients, 259 (4.6%) received an SGLT-2i at baseline. Reduction in UACR with finerenone was found with or without use of SGLT-2i at baseline, with ratio of least-squares means of 0.69 (95% CI = 0.66-0.71) and 0.75 (95% CI -= 0.62-0.90), respectively (P interaction = 0.31). Finerenone also significantly reduced the kidney and key secondary cardiovascular outcomes versus placebo; there was no clear difference in the results by SGLT-2i use at baseline (P interaction = 0.21 and 0.46, respectively) or at any time during the trial. Safety was balanced with or without SGLT-2i use at baseline, with fewer hyperkalemia events with finerenone in the SGLT-2i group (8.1% vs. 18.7% without).

Conclusion: UACR improvement was observed with finerenone in patients with CKD and T2D already receiving SGLT-2is at baseline, and benefits on kidney and cardiovascular outcomes appear consistent irrespective of use of SGLT-2i.

Keywords: albuminuria; chronic kidney disease; finerenone; sodium-glucose cotransporter-2 inhibitors; type 2 diabetes.

© 2021 International Society of Nephrology. Published by Elsevier Inc.

PubMed Disclaimer

Figures

None

Graphical abstract

Figure 1

Figure 1

Analysis of primary and secondary composite outcomes by baseline SGLT-2i use. CV, cardiovascular; SGLT-2i, sodium-glucose cotransporter-2 inhibitor.

Figure 2

Figure 2

Effect on albuminuria over time by baseline SGLT-2i use. Mixed-model analysis of UACR levels in patients who were (a) with or (b) without an SGLT-2i at baseline. Analysis included the following covariates: treatment group, stratification factors (region, albuminuria category at screening, eGFR category at screening), time, treatment over time, log-transformed baseline value nested within type of albuminuria at screening, and log-transformed baseline value over time. The change in UACR at month 4 was consistent irrespective of treatment with an SGLT-2i at baseline (_P_interaction = 0.31). eGFR, estimated glomerular filtration rate; SGLT-2i, sodium-glucose cotransporter-2 inhibitor; LS, least-squares; UACR, urine albumin-to-creatinine ratio.

Similar articles

Cited by

References

    1. Incidence, prevalence, patient characteristics, and treatment modalities United States Renal Data System. Published 2020. Accessed 13 April 2021. https://adr.usrds.org/2020/end-stage-renal-disease/1-incidence-prevalenc...
    1. Wu B., Bell K., Stanford A., et al. Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns-NHANES 2007–2012. BMJ Open Diabetes Res Care. 2016;4 doi: 10.1136/bmjdrc-2015-000154. - DOI - PMC - PubMed
    1. Piperidou A., Loutradis C., Sarafidis P. SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives. J Hum Hypertens. 2021;35:12–25. doi: 10.1038/s41371-020-00393-4. - DOI - PubMed
    1. American Diabetes Association Standards of medical care in diabetes-2021. Diabetes Care. 2021;44(suppl 1):S1–S244. doi: 10.2337/dc21-Sdis. - DOI - PubMed
    1. Buse J.B., Wexler D.J., Tsapas A., et al. 2019 update to: management of hyperglycaemia in type 2 diabetes, 2018 A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [published correction appears in Diabetologia. 2020;63:1667] Diabetologia. 2020;63:221–228. doi: 10.1007/s00125-019-05039-w. - DOI - PubMed

LinkOut - more resources